Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data.
about
Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment optionsZiprasidone versus other atypical antipsychotics for schizophreniaThe relationship between neurocognition and symptomatology in people with schizophrenia: social cognition as the mediatorPsychosocial treatments for negative symptoms in schizophrenia: current practices and future directions.Revisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: a meta-analysis.The assessment of quality of life in clinical practice in patients with schizophrenia.Brain structural signatures of negative symptoms in depression and schizophreniaImpact of negative symptoms on healthcare resource utilization and associated costs in adult outpatients with schizophrenia: a population-based study.Clinical correlates of parametric digit-symbol substitution test in schizophrenia.The effects of bupropion on negative symptoms in schizophreniaSocial competence versus negative symptoms as predictors of real world social functioning in schizophrenia.Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia.Apathy but not diminished expression in schizophrenia is associated with discounting of monetary rewards by physical effort.Clinical predictors of therapeutic response to antipsychotics in schizophreniaIncreased dopamine D2 receptor activity in the striatum alters the firing pattern of dopamine neurons in the ventral tegmental area.Reciprocal social behavior in youths with psychotic illness and those at clinical high risk.Course of neurological soft signs in first-episode schizophrenia: Relationship with negative symptoms and cognitive performancesConfirmatory Factor Analysis and Differential Relationships of the Two Subdomains of Negative Symptoms in Chronically Ill Psychotic Patients.Psychosocial functioning in schizophrenia: are some symptoms or demographic characteristics predictors across the functioning domains?Determinants of subjective and objective burden of informal caregiving of patients with psychotic disorders.The brief negative symptom scale: validation of the German translation and convergent validity with self-rated anhedonia and observer-rated apathy.Epidemiology and Treatment Guidelines of Negative Symptoms in Schizo-phrenia in Central and Eastern Europe: A Literature Review.Insular Gray Matter Volume and Objective Quality of Life in Schizophrenia.Disability assessment as an outcome measure: a comparative study of Nigerian outpatients with schizophrenia and healthy controlSchizophrenia in translation: dissecting motivation in schizophrenia and rodents.Social affiliation and negative symptoms in schizophrenia: Examining the role of behavioral skills and subjective respondingSelf-assessment of functional ability in schizophrenia: milestone achievement and its relationship to accuracy of self-evaluation.Measuring negative symptoms in patients with schizophrenia: reliability and validity of the Korean version of the Motivation and Pleasure Scale-Self-ReportMotivational and Behavioral Activation as an Adjunct to Psychiatric Rehabilitation for Mild to Moderate Negative Symptoms in Individuals with Schizophrenia: A Proof-of-Concept Pilot Study.Associations between social cognition, skills, and function and subclinical negative and positive symptoms in 22q11.2 deletion syndrome.Self-efficacy and functional status in schizophrenia: relationship to insight, cognition and negative symptomsEfficacy and Safety of Bitopertin in Patients with Schizophrenia and Predominant Negative Symptoms: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 2 Trial.Re-conceptualizing ASD Within a Dimensional Framework: Positive, Negative, and Cognitive Feature Clusters.Modified Mediterranean Diet for Enrichment of Short Chain Fatty Acids: Potential Adjunctive Therapeutic to Target Immune and Metabolic Dysfunction in Schizophrenia?Vitamin supplementation in the treatment of schizophrenia.Dissecting negative symptoms in schizophrenia: opportunities for translation into new treatments.A systematic review and meta-analysis of exercise interventions in schizophrenia patients.Oxytocin effects in schizophrenia: Reconciling mixed findings and moving forward.Confirmatory factor analysis of the quality of life scale and new proposed factor structure for the quality of life scale-revised.Burden of illness of people with persistent symptoms of schizophrenia: A multinational cross-sectional study.
P2860
Q22241447-164AC12F-DE4D-4808-876F-66CF434013ECQ24240260-9A80F395-1703-4B44-9C88-C54537B26040Q33633449-C3AAE739-1EA7-4729-BE9F-D7C248455115Q33882729-E3044512-F410-4C5C-8C6B-49123882E12FQ34022882-079DD541-5709-4833-8A4B-845AEF91002BQ34074662-9C9ECB24-6AAD-44AA-B886-F3F53A9D473AQ34093633-603E041F-A7AC-4A94-A70F-8E8B0173A7CDQ34109212-9FB37FDB-E9CE-4FE5-8BDA-490B05CF5C0AQ34142053-1C836461-2863-408F-98BF-A98FCF044F74Q34515916-BFDFABDA-F782-410B-A516-E4803551FFE3Q34644126-3CA6F119-5618-438E-9079-4361505D4810Q34822992-650724D8-93C8-4B5D-9D33-CC58D6678DC8Q35096548-04965173-BAC9-41DC-A799-2C88BDD2C70DQ35109168-6C2B5899-1363-4698-A7B5-2F14E4827B99Q35229331-C31382E2-8159-47F2-AEFA-13B6F238F9A8Q35559916-79D42393-F550-40BF-8CAB-EC62BB2852D4Q35693485-FDE407FC-368B-49EB-BDF1-1B2E6F7F40E1Q35928639-2FA1E161-DDF5-44A5-88F0-BD2C72789BFBQ36140353-E836DB4E-9067-4697-869A-ED19A23F2590Q36146756-8DD797D8-830E-476B-8DB7-05A6BB2F26EFQ36201440-0D5A91E0-69AB-40AB-8715-4574BFB3DEF1Q36232324-B86F7C16-461E-46DC-B98E-EEE34510175EQ36257468-B24F3FBA-AFC5-48BF-900B-F39D9488923CQ36307820-9E47103A-2528-4ED8-B31D-746F0004F028Q36386319-EC9AE781-D3C7-4E4E-A474-BFF5BD854733Q36602613-E04BB565-47A7-464E-BCB8-9506F2DCD99DQ36808021-0B5D8FDC-42E0-4BDB-B5BF-152FFE4531B2Q36908425-7CAEF0D6-3453-46BF-8527-8EBF8B4BE0DCQ37411272-D82B3182-0442-438D-97E3-32644657195FQ37419446-1B428B71-C5FC-43F7-B9E0-D50844F16D8AQ37529499-0035F6E6-3437-4D82-A587-94B889A4AA0FQ37589466-EB12DD3C-C594-468E-B747-220D2B0DB7FDQ37670079-691710A6-857F-462E-97A4-0A30F7E886FFQ37721268-0B14F2CB-B90B-4A2B-9594-3DDC9E627703Q38213305-9912FBAE-184A-43ED-B83B-F13C34511BB9Q38291334-9D9B1B2E-80E8-40A6-9E14-2A4EAED28B7BQ38343793-E9EF6842-9742-4FD7-8348-9170E198A141Q38683538-F91DFF1F-6456-4F98-B376-84D8FF159948Q38809282-2C4477AB-7011-44A3-9627-2D82C4219D7FQ38992595-37B1488C-99AE-4475-8D8E-9E87258816F0
P2860
Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data.
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Negative symptoms have greater ...... renia: analysis of CATIE data.
@ast
Negative symptoms have greater ...... renia: analysis of CATIE data.
@en
Negative symptoms have greater ...... renia: analysis of CATIE data.
@nl
type
label
Negative symptoms have greater ...... renia: analysis of CATIE data.
@ast
Negative symptoms have greater ...... renia: analysis of CATIE data.
@en
Negative symptoms have greater ...... renia: analysis of CATIE data.
@nl
prefLabel
Negative symptoms have greater ...... renia: analysis of CATIE data.
@ast
Negative symptoms have greater ...... renia: analysis of CATIE data.
@en
Negative symptoms have greater ...... renia: analysis of CATIE data.
@nl
P2093
P1476
Negative symptoms have greater ...... renia: analysis of CATIE data.
@en
P2093
Carmen Galani Berardo
Dragana Bugarski-Kirola
George Garibaldi
Jonathan Rabinowitz
Stephen Z Levine
P304
P356
10.1016/J.SCHRES.2012.01.015
P407
P50
P577
2012-02-06T00:00:00Z